Likewise, in on-going clinical trials testing MEK and BRAF inhibitors in KRAS- and BRAF-mutant lung cancer, responses have been reported in some patients (Blumenschein et al., 2015; Hyman et al., 2015). This evidence concerns the gene MAP2K7 and lung carcinoma.